[Advanced prostate cancer: sequence of androgen receptor-targeted substances and chemotherapy determines long-term survival].
暂无分享,去创建一个
T. Todenhöfer | P. Goebell | C. Schwentner | M. Schostak | C. Wülfing | S. Machtens | R. Tauber | R. Eichenauer | C. Lange
[1] F. Saad,et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.
[2] T. Tammela,et al. Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). , 2020 .
[3] F. Saad,et al. Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). , 2020 .
[4] J. Carles,et al. Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study. , 2020 .
[5] M. Gleave,et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. , 2019, The Lancet. Oncology.
[6] O. Sartor,et al. Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA , 2019, Annals of Oncology.
[7] N. Agarwal,et al. PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations , 2019, Annals of Oncology.
[8] J. Carles,et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.
[9] H. Gelderblom,et al. Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. , 2019, Clinical genitourinary cancer.
[10] M. Sydes,et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] A. Villers,et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Stockler,et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.
[13] N. Agarwal,et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. , 2019, The New England journal of medicine.
[14] S. Culine,et al. Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC). , 2019, Journal of Clinical Oncology.
[15] F. Saad,et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. , 2019, The Lancet. Oncology.
[16] D. Spaeth,et al. Clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis, whatever the treatment-line: Results of the CATS retrospective registry. , 2019, Journal of Clinical Oncology.
[17] A. Villers,et al. Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial. , 2019, Journal of Clinical Oncology.
[18] T. Tammela,et al. Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer , 2019, The New England journal of medicine.
[19] J. Carles,et al. An observational, multicentre study of cabazitaxel in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel (CAPRISTANA) , 2018, BJU international.
[20] A. Armstrong,et al. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. , 2019, European urology oncology.
[21] E. Esteban,et al. Results of the FLAC European Database of Metastatic Castration‐Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents , 2018, Clinical genitourinary cancer.
[22] M. Borre,et al. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] F. Saad,et al. Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.
[24] A. Fourrier-Réglat,et al. Cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): Real-life use, effectiveness, safety, and quality of life (QoL) in the FUJI cohort. , 2018 .
[25] F. Saad,et al. Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.
[26] A. Ravaud,et al. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. , 2017, European urology.
[27] D. Betticher,et al. Quality of Life in Second‐Line Treatment of Metastatic Castration‐Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry , 2017, Clinical genitourinary cancer.
[28] J. Carles,et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Y. Park,et al. Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer , 2017, The New England journal of medicine.
[30] T. Ecke,et al. Quality of life and pain relief in men with metastatic castration‐resistant prostate cancer on cabazitaxel: the non‐interventional ‘QoLiTime’ study , 2017, BJU international.
[31] Oliver Sartor,et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] R. Laing,et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.
[33] G. Tortora,et al. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. , 2015, Critical reviews in oncology/hematology.
[34] David F Jarrard,et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.
[35] C. V. von Klot,et al. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. , 2015, European urology.
[36] I. Tannock,et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] A. Bergman,et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment , 2014, Cancer.
[38] M. Kuczyk,et al. Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer , 2014, Advances in Therapy.
[39] M. Cronauer,et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. , 2014, European urology.
[40] J. Bono,et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. , 2014, European journal of cancer.
[41] F. Saad,et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] A. Armstrong,et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] J. Bono,et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] B. Tombal,et al. Access to information and expectations of treatment decisions for prostate cancer patients--results of a European survey. , 2013, European journal of cancer care.